Cargando…
VSL#3 induces and maintains short-term clinical response in patients with active microscopic colitis: a two-phase randomised clinical trial
BACKGROUND: The probiotic mixture VSL#3 has proven efficacious in inflammatory bowel diseases and irritable bowel syndrome; however, its efficacy in microscopic colitis (MC) is being investigated. OBJECTIVE: To evaluate the safety and efficacy of a multistrain probiotic, VSL#3, in inducing clinical...
Autores principales: | Rohatgi, Sarika, Ahuja, Vineet, Makharia, Govind K, Rai, Tarun, Das, Prasenjit, Dattagupta, Siddharth, Mishra, Veena, Garg, Sushil Kumar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599154/ https://www.ncbi.nlm.nih.gov/pubmed/26462271 http://dx.doi.org/10.1136/bmjgast-2014-000018 |
Ejemplares similares
-
Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study
por: Tursi, Antonio, et al.
Publicado: (2010) -
Budesonide as induction therapy for incomplete microscopic colitis: A randomised, placebo‐controlled multicentre trial
por: Münch, Andreas, et al.
Publicado: (2021) -
Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022) -
Reporting of endoscopy and histology of ulcerative colitis in routine clinical practice: How far we are!
por: Magro, Fernando, et al.
Publicado: (2023) -
Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial
por: Münch, Andreas, et al.
Publicado: (2016)